Publications by authors named "Daniel Mcclernon"

Claim this Profile
L
Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study.
Albert M Anderson, Bin Tang, Florin Vaida, Daniel Mcclernon, Reena Deutsch

J Acquir Immune Defic Syndr· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy.
Albert M Anderson, Suprateek Kundu, Bin Tang, Florin Vaida, Oluwakemi Okwuegbuna, Daniel McClernon

J Neuroimmunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
Albert M Anderson, Jose A Muñoz-Moreno, Daniel R McClernon, Ronald J Ellis, Debra Cookson

J Infect Dis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
José R Santos, José A Muñoz-Moreno, José Moltó, Anna Prats, Adrià Curran, Daniel R McClernon

PLoS One· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).
Princy N Kumar, Patricia Salvato, Anthony LaMarca, Edwin DeJesus, Parul Patel, Daniel McClernon

AIDS Res Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.
Jeffrey J Sevigny, Steven M Albert, Michael P McDermott, Giovanni Schifitto, Justin C McArthur, Daniel R McClernon

Arch Neurol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.
Matthew Bidwell Goetz, Monique R Ferguson, Xueliang Han, Greg McMillan, Marty St Clair, Daniel R McClernon

J Acquir Immune Defic Syndr· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
Justin C McArthur, Michael P McDermott, Daniel McClernon, Coryse St Hillaire, Kathy Conant

Arch Neurol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.
Cynthia McCoig, Maria Mercedes Castrejón, Elizabeth Castaño, Onix De Suman, Carmen Báez, Daniel McClernon

J Pediatr· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
Larry R Kirkland, Margaret A Fischl, Karen T Tashima, David Paar, Thomas Gensler, Daniel R McClernon

Clin Infect Dis· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis